Description:
Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is used in the treatment of certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma.
- Molecular Weight:444.48
- Boiling Point:805.7±65.0 °C at 760 mmHg
- Melting Point:170-174ºC
- Purity:>98%
Molecular Formula:
C22H28N4O6
Canonical SMILES:
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
InChI:
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey:
KKZJGLLVHKMTCM-UHFFFAOYSA-N
Solubility:
In vitro: 10 mM in DMSO
Appearance:
Brown to black (Solid)
Application:
Analgesics
Storage: 4°C, protect from light * In solvent : -80°C, 6 months -20°C, 1 month (protect from light)
Synonyms:
mitoxantrone; 65271-80-9; Mitoxanthrone; Mitozantrone; DHAQ Weitere Informationen finden Sie
hier